Identification

Name
Benzphetamine
Accession Number
DB00865  (APRD00759)
Type
Small Molecule
Groups
Approved, Illicit
Description

A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

Structure
Thumb
Synonyms
  • (+)-benzphetamine
  • (+)-N-Benzyl-N,alpha-dimethylphenethylamine
  • (+)-N-benzyl-N,α-dimethylphenethylamine
  • (+)-N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine
  • (+)-N,α-dimethyl-N-(phenylmethyl)-benzeneethanamine
  • (AlphaS)-N,alpha-dimethylphenethylamine
  • (S)-(+)-benzphetamine
  • (S)-(+)-N-Benzyl-N,alpha-dimethylphenethylamine
  • (S)-(+)-N-benzyl-N,α-dimethylphenethylamine
  • (S)-benzphetamine
  • Benzaphetamine
  • Benzfetamina
  • Benzfetamine
  • Benzfetaminum
  • Benzphetamine
  • Benzylamphetamine
  • D-N-Methyl-N-benzyl-beta-phenylisopropylamine
  • d-N-methyl-N-benzyl-β-phenylisopropylamine
  • N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine
Product Ingredients
IngredientUNIICASInChI Key
Benzphetamine Hydrochloride43DWT87QT75411-22-3ANFSNXAXVLRZCG-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DidrexTablet50 mg/1OralA S Medication Solutions1960-10-262017-06-20Us
DidrexTablet50 mg/1OralPharmacia & Upjohn Inc1960-10-262015-12-29Us
DidrexTablet50 mg/1OralA S Medication Solutions1960-10-262017-06-20Us
DidrexTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.1960-10-262016-12-23Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenzphetamineTablet25 mg/1OralTedor Pharma Inc.2016-02-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2008-12-012016-11-15Us
Benzphetamine HydrochlorideTablet50 mg/1OralApotheca, Inc.2009-12-09Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC2010-09-07Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.2011-11-01Not applicableUs
Benzphetamine HydrochlorideTablet, film coated50 mg/1OralEpic Pharma, LLC2015-12-16Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralA S Medication Solutions2010-07-212017-06-20Us
Benzphetamine HydrochlorideTablet50 mg/1OralC.O. Truxton, Inc.2011-11-01Not applicableUs
Benzphetamine HydrochlorideTablet50 mg/1OralA S Medication Solutions2010-07-212017-06-20Us
Benzphetamine HydrochlorideTablet, film coated50 mg/1OralHeritage2012-10-19Not applicableUs
Categories
UNII
0M3S43XK27
CAS number
156-08-1
Weight
Average: 239.3553
Monoisotopic: 239.167399677
Chemical Formula
C17H21N
InChI Key
YXKTVDFXDRQTKV-HNNXBMFYSA-N
InChI
InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
IUPAC Name
benzyl(methyl)[(2S)-1-phenylpropan-2-yl]amine
SMILES
C[[email protected]@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1

Pharmacology

Indication

For the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction

Structured Indications
Pharmacodynamics

Benzphetamine, a phenylalkylamin, is related to amphetamine both chemically and pharmacologically. It is an anorectic agent indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Mechanism of action

Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors.

TargetActionsOrganism
ASynaptic vesicular amine transporter
inducer
Human
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-1A adrenergic receptor
agonist
Human
USodium-dependent dopamine transporter
inhibitor
Human
Absorption

Readily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.

Volume of distribution
Not Available
Protein binding

75-99%

Metabolism

Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine.

Route of elimination
Not Available
Half life

16 to 31 hours

Clearance
Not Available
Toxicity

LD50=160 mg/kg (orally in rats). Acute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Benzphetamine.Experimental
AcebutololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Benzphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Benzphetamine.Approved
AcrivastineBenzphetamine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineBenzphetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilBenzphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Experimental
AlimemazineBenzphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
AlphacetylmethadolBenzphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineBenzphetamine may increase the analgesic activities of Alphaprodine.Illicit
AlprenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Benzphetamine.Illicit, Withdrawn
AmiodaroneThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Benzphetamine.Approved
Ammonium chlorideThe serum concentration of Benzphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Benzphetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Benzphetamine.Approved, Illicit
AntazolineBenzphetamine may decrease the sedative activities of Antazoline.Approved
AprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
ArotinololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Benzphetamine.Approved
AstemizoleBenzphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Benzphetamine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Benzphetamine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Benzphetamine.Investigational, Vet Approved
AzatadineBenzphetamine may decrease the sedative activities of Azatadine.Approved
AzelastineBenzphetamine may decrease the sedative activities of Azelastine.Approved
BamipineBenzphetamine may decrease the sedative activities of Bamipine.Experimental
BefunololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Benzphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Benzphetamine.Investigational
BetaxololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BezitramideBenzphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Benzphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
BisoprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe metabolism of Benzphetamine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Benzphetamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Benzphetamine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Benzphetamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of Benzphetamine.Investigational
BrompheniramineBenzphetamine may decrease the sedative activities of Brompheniramine.Approved
BucindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuclizineBenzphetamine may decrease the sedative activities of Buclizine.Approved
BufuralolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineBenzphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Benzphetamine.Experimental
ButorphanolBenzphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidBenzphetamine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
CarbamazepineThe metabolism of Benzphetamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineBenzphetamine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilBenzphetamine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Benzphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Benzphetamine.Withdrawn
CarteololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Benzphetamine can be increased when it is combined with Ceritinib.Approved
CetirizineBenzphetamine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineBenzphetamine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineBenzphetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineBenzphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Benzphetamine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Benzphetamine.Approved, Investigational, Withdrawn
CimetidineBenzphetamine may decrease the sedative activities of Cimetidine.Approved
CinnarizineBenzphetamine may decrease the sedative activities of Cinnarizine.Approved, Investigational
CitalopramThe metabolism of Benzphetamine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Benzphetamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Benzphetamine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Benzphetamine.Experimental
ClopidogrelThe metabolism of Benzphetamine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Benzphetamine.Experimental
ClotrimazoleThe metabolism of Benzphetamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of Benzphetamine.Approved
CobicistatThe metabolism of Benzphetamine can be decreased when combined with Cobicistat.Approved
CodeineBenzphetamine may increase the analgesic activities of Codeine.Approved, Illicit
ConivaptanThe serum concentration of Benzphetamine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Benzphetamine can be decreased when combined with Crizotinib.Approved
CyamemazineCyamemazine may decrease the stimulatory activities of Benzphetamine.Approved
CyclizineBenzphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Benzphetamine.Approved
CyclosporineThe metabolism of Benzphetamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineBenzphetamine may decrease the sedative activities of Cyproheptadine.Approved
DabrafenibThe serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Benzphetamine.Approved
DarunavirThe metabolism of Benzphetamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Benzphetamine can be decreased when combined with Delavirdine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Benzphetamine.Approved
DesloratadineBenzphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Benzphetamine.Approved
DexbrompheniramineBenzphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineBenzphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateBenzphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideBenzphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneBenzphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineBenzphetamine may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may decrease the antihypertensive activities of Benzphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
DihydrocodeineBenzphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Benzphetamine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineBenzphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineBenzphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Benzphetamine can be decreased when combined with Diltiazem.Approved
DimenhydrinateBenzphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneBenzphetamine may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazineBenzphetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineBenzphetamine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateBenzphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Benzphetamine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Benzphetamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dopamine.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Benzphetamine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Benzphetamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Doxofylline.Approved
DoxorubicinThe metabolism of Benzphetamine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Benzphetamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineBenzphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEBenzphetamine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Benzphetamine.Approved, Illicit
DronedaroneThe metabolism of Benzphetamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Benzphetamine.Approved
EbastineBenzphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Benzphetamine.Investigational
EmedastineBenzphetamine may decrease the sedative activities of Emedastine.Approved
EnzalutamideThe serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide.Approved
EpanololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ephedrine.Approved
EpinastineBenzphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Benzphetamine.Approved, Vet Approved
ErythromycinThe metabolism of Benzphetamine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Benzphetamine.Investigational
EsmololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EthopropazineBenzphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Withdrawn
EthylmorphineBenzphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Etilefrine.Withdrawn
EtorphineBenzphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineBenzphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Fenozolone.Experimental
FentanylBenzphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineBenzphetamine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Benzphetamine.Experimental
FluconazoleThe metabolism of Benzphetamine can be decreased when combined with Fluconazole.Approved
FlunarizineBenzphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Benzphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
FluvoxamineThe metabolism of Benzphetamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Benzphetamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Benzphetamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Benzphetamine can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Benzphetamine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Benzphetamine can be increased when it is combined with Fusidic Acid.Approved
Glutamic AcidThe serum concentration of Benzphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Benzphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Benzphetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Harmaline.Experimental
HeroinBenzphetamine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Benzphetamine.Experimental
HydrocodoneBenzphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneBenzphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Hydroxyamphetamine.Approved
HydroxyzineBenzphetamine may decrease the sedative activities of Hydroxyzine.Approved
IdelalisibThe serum concentration of Benzphetamine can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Benzphetamine.Approved
ImatinibThe metabolism of Benzphetamine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may decrease the antihypertensive activities of Benzphetamine.Approved
IndenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Benzphetamine can be decreased when combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Benzphetamine.Approved, Investigational
Ioflupane I-123Benzphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may decrease the antihypertensive activities of Benzphetamine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Benzphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Benzphetamine.Withdrawn
IsavuconazoniumThe metabolism of Benzphetamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Benzphetamine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoprenaline.Approved
IsothipendylBenzphetamine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Benzphetamine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Benzphetamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Benzphetamine can be increased when it is combined with Ivacaftor.Approved
KetobemidoneBenzphetamine may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Benzphetamine can be decreased when combined with Ketoconazole.Approved, Investigational
KetotifenBenzphetamine may decrease the sedative activities of Ketotifen.Approved
LabetalolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LafutidineBenzphetamine may decrease the sedative activities of Lafutidine.Investigational
LandiololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LavoltidineBenzphetamine may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineBenzphetamine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineBenzphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateBenzphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Benzphetamine.Approved
LevorphanolBenzphetamine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Benzphetamine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Benzphetamine.Approved
LodoxamideBenzphetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilBenzphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Benzphetamine.Experimental
LopinavirThe metabolism of Benzphetamine can be decreased when combined with Lopinavir.Approved
LoratadineBenzphetamine may decrease the sedative activities of Loratadine.Approved
LovastatinThe metabolism of Benzphetamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may decrease the stimulatory activities of Benzphetamine.Approved
LuliconazoleThe serum concentration of Benzphetamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Benzphetamine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Benzphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Benzphetamine.Withdrawn
MeclizineBenzphetamine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mefenorex.Experimental
MelperoneMelperone may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mephentermine.Approved
MepindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MeptazinolBenzphetamine may increase the analgesic activities of Meptazinol.Experimental
MepyramineBenzphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineBenzphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Benzphetamine.Approved, Investigational
MethadoneBenzphetamine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateBenzphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methamphetamine.Approved, Illicit
MethapyrileneBenzphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Benzphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Benzphetamine.Approved, Investigational
Methylene blueMethylene blue may increase the hypertensive activities of Benzphetamine.Approved, Investigational
MetiamideBenzphetamine may decrease the sedative activities of Metiamide.Experimental
MetoprololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Mianserin.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Benzphetamine.Approved
MifepristoneThe serum concentration of Benzphetamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may decrease the antihypertensive activities of Benzphetamine.Approved
MinaprineMinaprine may increase the hypertensive activities of Benzphetamine.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Benzphetamine.Approved
MitotaneThe serum concentration of Benzphetamine can be decreased when it is combined with Mitotane.Approved
MizolastineBenzphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Benzphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of Benzphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of Benzphetamine.Experimental
MorphineBenzphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Benzphetamine.Experimental
NabiloneNabilone may increase the tachycardic activities of Benzphetamine.Approved, Investigational
NadololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineBenzphetamine may increase the analgesic activities of Nalbuphine.Approved
NefazodoneThe metabolism of Benzphetamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Benzphetamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Benzphetamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Benzphetamine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Benzphetamine.Withdrawn
NicomorphineBenzphetamine may increase the analgesic activities of Nicomorphine.Experimental
NilotinibThe metabolism of Benzphetamine can be decreased when combined with Nilotinib.Approved, Investigational
NizatidineBenzphetamine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Benzphetamine.Approved
NormethadoneBenzphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Benzphetamine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Benzphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
OlaparibThe metabolism of Benzphetamine can be decreased when combined with Olaparib.Approved
OlopatadineBenzphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Benzphetamine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Benzphetamine.Investigational
OpiumBenzphetamine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Benzphetamine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Benzphetamine.Investigational
OsimertinibThe serum concentration of Benzphetamine can be increased when it is combined with Osimertinib.Approved
OxatomideBenzphetamine may decrease the sedative activities of Oxatomide.Investigational
OxprenololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxycodoneBenzphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Oxymetazoline.Approved
OxymorphoneBenzphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Benzphetamine.Experimental
OzagrelBenzphetamine may decrease the sedative activities of Ozagrel.Investigational
PalbociclibThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Benzphetamine.Approved
PargylinePargyline may increase the hypertensive activities of Benzphetamine.Approved
ParoxetineThe metabolism of Benzphetamine can be decreased when combined with Paroxetine.Approved, Investigational
PemirolastBenzphetamine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenbutololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Benzphetamine.Experimental
PentazocineBenzphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Benzphetamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Benzphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Benzphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Benzphetamine.Approved
PethidineBenzphetamine may increase the analgesic activities of Pethidine.Approved
PhenazocineBenzphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Benzphetamine.Approved
PhenindamineBenzphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Benzphetamine.Withdrawn
PheniramineBenzphetamine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Benzphetamine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Benzphetamine.Approved
PhenoperidineBenzphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Benzphetamine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Benzphetamine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Benzphetamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Benzphetamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Benzphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Benzphetamine.Approved
PindololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperonePipamperone may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
PiritramideBenzphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Benzphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Benzphetamine.Withdrawn
PosaconazoleThe metabolism of Benzphetamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Prenalterol.Experimental
PrimidoneThe metabolism of Benzphetamine can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
PromethazineBenzphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Benzphetamine.Approved
PropranololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Benzphetamine.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Benzphetamine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pseudoephedrine.Approved
QuazepamThe serum concentration of Benzphetamine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineQuetiapine may decrease the stimulatory activities of Benzphetamine.Approved
QuifenadineBenzphetamine may decrease the sedative activities of Quifenadine.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Benzphetamine.Investigational
RanitidineBenzphetamine may decrease the sedative activities of Ranitidine.Approved
RanolazineThe metabolism of Benzphetamine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Benzphetamine.Approved
RemifentanilBenzphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
RifabutinThe metabolism of Benzphetamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Benzphetamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Benzphetamine can be increased when combined with Rifapentine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Benzphetamine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Benzphetamine can be decreased when combined with Ritonavir.Approved, Investigational
Roxatidine acetateBenzphetamine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Benzphetamine.Withdrawn
SaquinavirThe metabolism of Benzphetamine can be decreased when combined with Saquinavir.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Benzphetamine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Benzphetamine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Benzphetamine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Benzphetamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Benzphetamine can be increased when it is combined with Simeprevir.Approved
SorafenibThe metabolism of Benzphetamine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolBenzphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
St. John's WortThe serum concentration of Benzphetamine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Benzphetamine can be increased when it is combined with Stiripentol.Approved
SufentanilBenzphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Benzphetamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Benzphetamine.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Synephrine.Experimental
TalinololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TapentadolBenzphetamine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Benzphetamine.Approved
TelaprevirThe metabolism of Benzphetamine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Benzphetamine can be decreased when combined with Telithromycin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Terbutaline.Approved
TerfenadineBenzphetamine may decrease the sedative activities of Terfenadine.Withdrawn
TertatololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TesmilifeneBenzphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Benzphetamine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tetryzoline.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Benzphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Benzphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Benzphetamine.Approved, Withdrawn
ThiotepaThe metabolism of Benzphetamine can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Benzphetamine.Approved
ThonzylamineBenzphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Benzphetamine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
TiclopidineThe metabolism of Benzphetamine can be decreased when combined with Ticlopidine.Approved
TilidineBenzphetamine may increase the analgesic activities of Tilidine.Experimental
TimololBenzphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TocilizumabThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.Approved
ToloxatoneToloxatone may increase the hypertensive activities of Benzphetamine.Approved
TramadolBenzphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tramazoline.Investigational
TranilastBenzphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benzphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Benzphetamine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Benzphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Benzphetamine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Benzphetamine.Approved
TripelennamineBenzphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineBenzphetamine may decrease the sedative activities of Triprolidine.Approved
TritoqualineBenzphetamine may decrease the sedative activities of Tritoqualine.Experimental
TyramineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tyramine.Investigational, Nutraceutical
VenlafaxineThe metabolism of Benzphetamine can be decreased when combined with Venlafaxine.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Benzphetamine.Experimental
VerapamilThe metabolism of Benzphetamine can be decreased when combined with Verapamil.Approved
Vitamin CThe serum concentration of Benzphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Benzphetamine can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Benzphetamine can be decreased when combined with Ziprasidone.Approved
ZotepineZotepine may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Benzphetamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Dennis J. Kalota, Keith G. Tomazi, "Crystallization Method for Benzphetamine." U.S. Patent US20080262268, issued October 23, 2008.

US20080262268
General References
Not Available
External Links
Human Metabolome Database
HMDB15003
KEGG Compound
C07538
PubChem Compound
5311017
PubChem Substance
46506102
ChemSpider
4470556
ChEBI
3044
ChEMBL
CHEMBL3545985
Therapeutic Targets Database
DAP001147
PharmGKB
PA448586
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Benzphetamine
MSDS
Download (16.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Corepharma llc
  • Impax laboratories inc
  • Kvk tech inc
  • Paddock laboratories inc
  • Tedor pharma inc
  • Tyco healthcare mallinckrodt
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
TabletOral50 mg/1
Tablet, film coatedOral50 mg/1
TabletOral25 mg/1
Prices
Unit descriptionCostUnit
Didrex 50 mg tablet1.71USD tablet
Benzphetamine hcl 50 mg tablet1.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)129-130Heinzelman, R.V. and Aspergren, B.D.; US. Patent 2,789,138; April 16,1957; assigned to The Upjohn Company.
water solubilityReadily solubleNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0233 mg/mLALOGPS
logP3.72ALOGPS
logP4.34ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity78.39 m3·mol-1ChemAxon
Polarizability29.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9864
Caco-2 permeable+0.8815
P-glycoprotein substrateSubstrate0.541
P-glycoprotein inhibitor INon-inhibitor0.8803
P-glycoprotein inhibitor IINon-inhibitor0.9437
Renal organic cation transporterInhibitor0.7013
CYP450 2C9 substrateNon-substrate0.769
CYP450 2D6 substrateNon-substrate0.588
CYP450 3A4 substrateNon-substrate0.5135
CYP450 1A2 substrateInhibitor0.8684
CYP450 2C9 inhibitorNon-inhibitor0.9146
CYP450 2D6 inhibitorInhibitor0.539
CYP450 2C19 inhibitorNon-inhibitor0.5997
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8047
Ames testNon AMES toxic0.888
CarcinogenicityNon-carcinogens0.6584
BiodegradationNot ready biodegradable0.9825
Rat acute toxicity3.1442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8779
hERG inhibition (predictor II)Non-inhibitor0.5331
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.86 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Phenylmethylamines / Benzylamines / Aralkylamines / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / Phenylmethylamine / Benzylamine / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amine, amphetamines (CHEBI:3044)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Monoamine transmembrane transporter activity
Specific Function
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles...
Gene Name
SLC18A2
Uniprot ID
Q05940
Uniprot Name
Synaptic vesicular amine transporter
Molecular Weight
55712.075 Da
References
  1. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613]
  2. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A: Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3495-500. Epub 2005 Feb 22. [PubMed:15728379]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA: Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. [PubMed:8486332]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Bumpus NN, Sridar C, Kent UM, Hollenberg PF: The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos. 2005 Jun;33(6):795-802. Epub 2005 Mar 15. [PubMed:15769884]
  2. Shebley M, Kent UM, Ballou DP, Hollenberg PF: Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52. doi: 10.1124/dmd.108.024661. Epub 2009 Jan 14. [PubMed:19144770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name
POR
Uniprot ID
P16435
Uniprot Name
NADPH--cytochrome P450 reductase
Molecular Weight
76689.12 Da
References
  1. Kanaeva IP, Nikityuk OV, Davydov DR, Dedinskii IR, Koen YM, Kuznetsova GP, Skotselyas ED, Bachmanova GI, Archakov AI: Comparative study of monomeric reconstituted and membrane microsomal monooxygenase systems of the rabbit liver. II. Kinetic parameters of reductase and monooxygenase reactions. Arch Biochem Biophys. 1992 Nov 1;298(2):403-12. [PubMed:1416971]
  2. Matsumoto T, Emi Y, Kawabata S, Omura T: Purification and characterization of three male-specific and one female-specific forms of cytochrome P-450 from rat liver microsomes. J Biochem. 1986 Nov;100(5):1359-71. [PubMed:2434473]
  3. Kojima H, Takahashi K, Sakane F, Koyama J: Purification and characterization of NADPH-cytochrome c reductase from porcine polymorphonuclear leukocytes. J Biochem. 1987 Nov;102(5):1083-8. [PubMed:3125159]
  4. Dutton DR, McMillen SK, Parkinson A: Purification of rat liver microsomal cytochrome P-450b without the use of nonionic detergent. J Biochem Toxicol. 1988 Summer;3:131-45. [PubMed:3148724]
  5. Halpert JR, Miller NE, Gorsky LD: On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403. [PubMed:3924914]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43